Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Schweiger Dermatology PC

Neither a doctor nor a teaching hospital

Research payments

$590,854

223 payments

Through program year 2025, Schweiger Dermatology PC is reported as receiving $590,854 in research payments, across 223 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $206,850 97
2024 Research $276,728 99
2023 Research $107,277 27

Breakdown

Who paid Research payments · program years 2023–2025
  1. AbbVie, Inc. $323,023 132 payments
  2. Sun Pharmaceutical Industries Inc. $174,381 75 payments
  3. Pfizer Inc. $50,343 12 payments
  4. Janssen Research & Development, LLC $21,868 3 payments
  5. Amgen Inc. $21,240 1 payment
Studies the money was for Research payments · program years 2023–2025
  1. Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata $164,546 73 payments
  2. BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study $83,169 15 payments
  3. A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) $69,501 52 payments
  4. A Phase 3 Openlabel Multicenter Longterm Study Investigating the Safety and Efficacy of Pf06651600 in Adult and Adolescent Participants With Alopecia Areata $50,343 12 payments
  5. BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study $37,653 2 payments
  6. A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) $32,738 21 payments
  7. M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study $26,125 3 payments
  8. A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis $21,868 3 payments
  9. P3 AD Adult Combo TCS $21,240 1 payment
  10. M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) $14,767 16 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record